Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study

This study aims to develop and validate a risk prediction model in the first year of ICI-based therapy. In addition to the primary aim, the study also aims to observe trajectories of patient reported quality of life, health preferences and patient reported adverse events over 12 months as well as to evaluate and track patterns of toxicities and adverse events.


  • Planning to receive immune checkpoint inhibitor-based therapy
  • 18 years of age or older

Locations: Hartford Hospital, Hartford HealthCare Cancer Institute at The Hospital of Central Connecticut, MidState Medical Center

Contacts: Hartford Region: 860-972-5371, Central Region: 860-696-4958

Sponsor: SWOG Cancer Research Network

Cancer Clinical Research Office